Point72 DIFC Ltd Acquires 181,161 Shares of LivaNova PLC (NASDAQ:LIVN)

Point72 DIFC Ltd grew its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 75,799.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 181,400 shares of the company’s stock after purchasing an additional 181,161 shares during the quarter. Point72 DIFC Ltd’s holdings in LivaNova were worth $9,531,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Hexagon Capital Partners LLC increased its holdings in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after buying an additional 370 shares during the last quarter. Fifth Third Bancorp increased its stake in shares of LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova in the 2nd quarter worth approximately $88,000. Central Pacific Bank Trust Division purchased a new position in LivaNova in the third quarter valued at approximately $178,000. Finally, TradeLink Capital LLC bought a new position in LivaNova during the second quarter valued at $208,000. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LIVN has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price target on shares of LivaNova in a research report on Monday, November 25th. The Goldman Sachs Group started coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 target price for the company. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Robert W. Baird raised their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $69.17.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $51.62 on Wednesday. The company has a 50 day moving average of $52.29 and a 200 day moving average of $51.95. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.80 billion, a P/E ratio of 122.90 and a beta of 0.98. LivaNova PLC has a 12 month low of $42.75 and a 12 month high of $64.47.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.